Canaccord Genuity Maintains Buy on Health Catalyst, Lowers Price Target to $2
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ:HCAT) with a Buy and lowers the price target from $5 to $2.
Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ:HCAT) with a Buy and lowers the price target from $5 to $2.